Maltby Steven, Hughes Michael R, Zbytnuik Lori, Paulson Robert F, McNagny Kelly M
The Biomedical Research Centre, The University of British Columbia, Vancouver, Canada.
Exp Hematol. 2009 Jan;37(1):10-8. doi: 10.1016/j.exphem.2008.09.006. Epub 2008 Nov 11.
Podocalyxin expression on Ter119(+) erythroblasts is induced following administration of erythropoietin (Epo) or phenylhydrazine treatment, but is notably absent on committed erythroid progenitors during homeostatic red cell turnover. Following high-dose Epo administration in vivo, podocalyxin surface expression is upregulated, in part, via a signal transducers and activators of transcription 5-dependent pathway and this expression has been postulated to play a role in the release of reticulocytes from hematopoietic organs into the periphery under conditions of increased erythropoietic rate. Here we have thoroughly addressed this hypothesis and further examined the expression profile of podocalyxin during Epo-induced erythroblast expansion and stress erythropoiesis.
Following Epo induction, progenitor cells were sorted to characterize podocalyxin expression during stress. In addition, as podocalyxin-deficient mice die perinatally, we used chimeric mice reconstituted with wild-type or podocalyxin-deficient hematopoietic cells to analyze differences in response to high dose Epo administration and chemically induced anemia.
Podocalyxin surface expression is rapidly upregulated in response to stress and marks early erythroid progenitors and erythroblasts. Despite loss of podocalyxin, chimeras exhibit normal basal erythropoiesis and no differences in erythroid progenitor proportions in the spleen and marrow in response to Epo. Further, podocalyxin is dispensable for efficient recovery from models of anemia.
We demonstrate that podocalyxin is a highly specific marker of stress-induced blast-forming unit erythroid and colony-forming unit erythroid progenitors in mouse bone marrow and spleen. In addition, our findings suggest that podocalyxin is not necessary for efficient erythroblast expansion, erythroid differentiation, or reticulocyte release in response to Epo stimulation in vivo.
促红细胞生成素(Epo)给药或苯肼处理后,Ter119(+)成红细胞上的足突细胞黏蛋白表达被诱导,但在稳态红细胞更新过程中,定向红细胞祖细胞上明显缺乏该表达。在体内给予高剂量Epo后,足突细胞黏蛋白的表面表达部分通过转录信号转导子和激活子5依赖性途径上调,并且这种表达被推测在造血率增加的情况下,对网织红细胞从造血器官释放到外周血中起作用。在此,我们全面验证了这一假设,并进一步研究了足突细胞黏蛋白在Epo诱导的成红细胞扩增和应激性红细胞生成过程中的表达谱。
Epo诱导后,对祖细胞进行分选,以表征应激期间足突细胞黏蛋白的表达。此外,由于足突细胞黏蛋白缺陷小鼠在围产期死亡,我们使用用野生型或足突细胞黏蛋白缺陷造血细胞重建的嵌合小鼠,来分析对高剂量Epo给药和化学诱导贫血的反应差异。
足突细胞黏蛋白表面表达在应激反应中迅速上调,并标记早期红细胞祖细胞和成红细胞。尽管缺乏足突细胞黏蛋白,但嵌合体表现出正常的基础红细胞生成,并且在对Epo的反应中,脾脏和骨髓中的红细胞祖细胞比例没有差异。此外,足突细胞黏蛋白对于从贫血模型中有效恢复并非必需。
我们证明,足突细胞黏蛋白是小鼠骨髓和脾脏中应激诱导的红细胞系爆式形成单位和红细胞系集落形成单位祖细胞的高度特异性标志物。此外,我们的研究结果表明,在体内对Epo刺激的反应中,足突细胞黏蛋白对于有效的成红细胞扩增、红细胞分化或网织红细胞释放并非必需。